Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... have developed a unique nanoscale device that for ... The discovery could have major implications for creating ... and communication. , The research paper by University ... Mo Li and his graduate student Huan Li ... the October issue of Nature Nanotechnology . ...
(Date:9/22/2014)... Rhinebeck, NY (PRWEB) September 22, 2014 ... commitment helping those in pain end their suffering, restoring ... sustainable healthcare model. This is only possible because of ... relief and healing cream technology a reality. , ... in Rhinebeck, NY, by Lou Paradise (president, chief of ...
(Date:9/22/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCBB:GNBT) today announced ... University Health Network (UHN) pursuant to which UHN,s ... spearhead the Company,s buccal insulin refinement project.  The ... insulin bioavailability of Generex Oral-lyn™, the Company,s proprietary ...
(Date:9/22/2014)... September 22, 2014 METTLER TOLEDO ... and pallet measuring device CNS110 ScanTape™ . ... data entry, offering greater ease and accuracy for ... result can significantly enhance productivity—an important benefit for ... processing volume equals profits. , Usable at ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... - Immunocytokine Combining Peregrine,s Anti-PS Antibodies and IL-2,Protected 80% of Animals From a Lethal Challenge ... ... at International Conference on Vascular Targeted, Therapies in Oncology Further Supports a Second ... ...
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... Corporation,(Nasdaq: IOMI ) today announced that Stanley C. ... at the Natixis,Bleichroeder Hidden Gems Conference in New York ... at 2:45 p.m. Eastern Time in the in,Union Square ... live audio webcast or the subsequent archived recording,log on ...
Cached Biology Technology:New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 2New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 3New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 4VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3
(Date:9/21/2014)... CAMBRIDGE, MA -- In recent years, new strains of ... antibiotics. Each year, these superbugs, including drug-resistant forms of ... nationwide, and kill at least 23,000. Despite the urgent ... new classes of antibiotics in the past decade. , ... on these superbugs. Using a gene-editing system that can ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... breath may indicate how susceptible they are to weight gain, ... Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... hydrogen and methane gases are more likely to have a ... to the findings. The combination of the two gases signals ...
... the early 1940s, California fishermen hauled in a historic bounty of ... "Cannery Row" novel. But by the end of the decade the ... all go? According to a new study led by scientists at ... the sardine mystery are a dynamic and interconnected moving target. ...
... March 25, 2013 Until now most experimental vaccines ... effectiveness. But a new vaccine has proven highly effective against ... is also effective against the H9 subtype of avian influenza. ... Journal of Virology . The strength of ...
Cached Biology News:Microorganisms detected via breath test linked to body mass, fat accumulation 2Predictions of climate impacts on fisheries can be a mirage 2Cleverly designed vaccine blocks H5 avian influenza in models 2
...
... SpliceArray service, ExonHit can design custom microarrays ... your gene list. Proprietary algorithms are ... microarray probes from high quality, spliced cDNAs ... event contained in a custom SpliceArray is ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
Biology Products: